ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Antibody-Suppressor CD8+ T Cells Require CXCR5

J. Zimmerer1, B. A. Ringwald1, C. L. Avila1, S. M. Elzein1, R. T. Warren1, M. Abdel-Rasoul2, G. L. Bumgardner1

1Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, 2Center for Biostatistics, The Ohio State University Wexner Medical Center, Columbus, OH

Meeting: 2019 American Transplant Congress

Abstract number: 171

Keywords: Alloantibodies, Rejection, T cells

Session Information

Session Name: Concurrent Session: B-cell / Antibody /Autoimmunity

Session Type: Concurrent Session

Date: Sunday, June 2, 2019

Session Time: 4:30pm-6:00pm

 Presentation Time: 5:30pm-5:42pm

Location: Room 310

*Purpose: We previously reported the novel activity of alloprimed CD8+ T cells that suppress post-transplant alloantibody production. The purpose of the current study was to investigate the expression and role of CXCR5 on antibody-suppressor CD8+ T cell (CD8+ TAb-supp cell) function.

*Methods: C57BL/6 mice were transplanted (Tx) with FVB/N hepatocytes (Hc). Alloprimed CD8+ T cells were retrieved on day 7 from hepatocyte Tx recipients and CD8+ T cell subsets were sorted into CXCR5+CXCR3– (9.3±1.0%) or CXCR3+CXCR5– (8.4±0.3%) subsets by flow cytometry (both subsets were CD44+IFN-γ+).

*Results: Flow-sorted (CXCR5+CXCR3– and CXCR3+CXCR5‑) alloprimed CD8+ T cell subsets were analyzed for in vitro cytotoxicity and capacity to inhibit in vivo alloantibody production following adoptive transfer (AT) into C57BL/6 or high alloantibody-producing CD8 KO hepatocyte Tx recipients. Alloprimed CXCR5+CXCR3–CD8+ T cells mediated in vitro cytotoxicity of alloprimed IgG+ (antibody-producing) B cells (12.7±1.8%, n=10, p<0.0001) while CXCR3+CXCR5–CD8+ T cells did not (1.9±1.9%, n=10, p=ns). Only flow-sorted alloprimed CXCR5+CXCR3–CD8+ T cells (not flow-sorted alloprimed CXCR3+CXCR5–CD8+ T cells) suppressed alloantibody production after AT into C57BL/6 HcTx recipients (titer=60±10 compared to 120±20 in untreated control HcTx mice, N≥4 in each group, p=0.02). The lower alloantibody titer following AT of CXCR5+CXCR3–CD8+ T cells into C57BL/6 recipients also correlated with a 2-fold reduction in the quantity of germinal center B cells (p=0.001) and IL-4+IL-21+ CD4+ TFH cells (p=0.003) compared to control recipients without AT. Adoptive transfer of CXCR5+CXCR3–CD8+ T cells also suppressed alloantibody production in high alloantibody-producing CD8 KO HcTx recipients (titer= 90±40 vs.1,300±500 in control mice, N≥5 in each group, p<0.0001). CD8 KO hepatocyte recipients that received AT of CXCR5+CXCR3–CD8+ T cells had prolonged allograft survival (MST=day 32; N=5, p=0.002) compared to those that received AT of CXCR3+CXCR5–CD8+ T cells (MST= day 14, N=5) or those with no AT (MST= day 14, N=7). Adoptive transfer of CD8+ T cells retrieved from wild-type (but not CXCR5 KO) mice into CD8 KO HcTx recipients suppresses alloantibody production (titer= 300±70 vs. 1,250±250 in control mice p=0.004).

*Conclusions: These data support the conclusion that expression of CXCR5 by antigen-primed CD8+ T cells is critical for the function of CD8+ TAb-supp cells.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Zimmerer J, Ringwald BA, Avila CL, Elzein SM, Warren RT, Abdel-Rasoul M, Bumgardner GL. Antibody-Suppressor CD8+ T Cells Require CXCR5 [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/antibody-suppressor-cd8-t-cells-require-cxcr5/. Accessed May 9, 2025.

« Back to 2019 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences